Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Identifieur interne : 000210 ( PubMed/Checkpoint ); précédent : 000209; suivant : 000211Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Auteurs : Guangdi Li ; Erik De ClercqSource :
- Nature reviews. Drug discovery [ 1474-1784 ] ; 2020.
Descripteurs français
- KwdFr :
- AMP (analogues et dérivés), AMP (usage thérapeutique), Alanine (analogues et dérivés), Alanine (usage thérapeutique), Antiviraux (usage thérapeutique), Coronavirus du syndrome respiratoire du Moyen-Orient (), Coronavirus du syndrome respiratoire du Moyen-Orient (génétique), Coronavirus du syndrome respiratoire du Moyen-Orient (pathogénicité), Glycoprotéine de spicule des coronavirus (), Grippe humaine (traitement médicamenteux), Humains, Hépatite B (traitement médicamenteux), Hépatite C (traitement médicamenteux), Infections à VIH (traitement médicamenteux), Infections à coronavirus (traitement médicamenteux), Inhibiteurs de protéases (pharmacologie), Inhibiteurs de protéases (usage thérapeutique), Interféron alpha (pharmacologie), Interféron alpha (usage thérapeutique), Nucléosides (pharmacologie), Nucléosides (usage thérapeutique), Pneumopathie virale (traitement médicamenteux), Polyéthylène glycols (pharmacologie), Polyéthylène glycols (usage thérapeutique), Protéines recombinantes (pharmacologie), Protéines recombinantes (usage thérapeutique), Repositionnement des médicaments, Virus du SRAS (), Virus du SRAS (génétique), Virus du SRAS (pathogénicité).
- MESH :
- analogues et dérivés : AMP, Alanine.
- génétique : Coronavirus du syndrome respiratoire du Moyen-Orient, Virus du SRAS.
- pathogénicité : Coronavirus du syndrome respiratoire du Moyen-Orient, Virus du SRAS.
- pharmacologie : Inhibiteurs de protéases, Interféron alpha, Nucléosides, Polyéthylène glycols, Protéines recombinantes.
- traitement médicamenteux : Grippe humaine, Hépatite B, Hépatite C, Infections à VIH, Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : AMP, Alanine, Antiviraux, Inhibiteurs de protéases, Interféron alpha, Nucléosides, Polyéthylène glycols, Protéines recombinantes.
- Coronavirus du syndrome respiratoire du Moyen-Orient, Glycoprotéine de spicule des coronavirus, Humains, Repositionnement des médicaments, Virus du SRAS.
English descriptors
- KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (therapeutic use), Alanine (analogs & derivatives), Alanine (therapeutic use), Antiviral Agents (therapeutic use), Betacoronavirus (drug effects), Betacoronavirus (genetics), Betacoronavirus (pathogenicity), Coronavirus Infections (drug therapy), Drug Repositioning, HIV Infections (drug therapy), Hepatitis B (drug therapy), Hepatitis C (drug therapy), Humans, Influenza, Human (drug therapy), Interferon-alpha (pharmacology), Interferon-alpha (therapeutic use), Middle East Respiratory Syndrome Coronavirus (drug effects), Middle East Respiratory Syndrome Coronavirus (genetics), Middle East Respiratory Syndrome Coronavirus (pathogenicity), Nucleosides (pharmacology), Nucleosides (therapeutic use), Pneumonia, Viral (drug therapy), Polyethylene Glycols (pharmacology), Polyethylene Glycols (therapeutic use), Protease Inhibitors (pharmacology), Protease Inhibitors (therapeutic use), Recombinant Proteins (pharmacology), Recombinant Proteins (therapeutic use), SARS Virus (drug effects), SARS Virus (genetics), SARS Virus (pathogenicity), Spike Glycoprotein, Coronavirus (drug effects).
- MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , drug effects : Spike Glycoprotein, Coronavirus.
- chemical , pharmacology : Interferon-alpha, Nucleosides, Polyethylene Glycols, Protease Inhibitors, Recombinant Proteins.
- chemical , therapeutic use : Adenosine Monophosphate, Alanine, Antiviral Agents, Interferon-alpha, Nucleosides, Polyethylene Glycols, Protease Inhibitors, Recombinant Proteins.
- drug effects : Betacoronavirus, Middle East Respiratory Syndrome Coronavirus, SARS Virus.
- drug therapy : Coronavirus Infections, HIV Infections, Hepatitis B, Hepatitis C, Influenza, Human, Pneumonia, Viral.
- genetics : Betacoronavirus, Middle East Respiratory Syndrome Coronavirus, SARS Virus.
- pathogenicity : Betacoronavirus, Middle East Respiratory Syndrome Coronavirus, SARS Virus.
- Drug Repositioning, Humans.
DOI: 10.1038/d41573-020-00016-0
PubMed: 32127666
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:32127666Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic options for the 2019 novel coronavirus (2019-nCoV).</title>
<author><name sortKey="Li, Guangdi" sort="Li, Guangdi" uniqKey="Li G" first="Guangdi" last="Li">Guangdi Li</name>
</author>
<author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32127666</idno>
<idno type="pmid">32127666</idno>
<idno type="doi">10.1038/d41573-020-00016-0</idno>
<idno type="wicri:Area/PubMed/Corpus">000849</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000849</idno>
<idno type="wicri:Area/PubMed/Curation">000849</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000849</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000210</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000210</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic options for the 2019 novel coronavirus (2019-nCoV).</title>
<author><name sortKey="Li, Guangdi" sort="Li, Guangdi" uniqKey="Li G" first="Guangdi" last="Li">Guangdi Li</name>
</author>
<author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
</author>
</analytic>
<series><title level="j">Nature reviews. Drug discovery</title>
<idno type="eISSN">1474-1784</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term>
<term>Adenosine Monophosphate (therapeutic use)</term>
<term>Alanine (analogs & derivatives)</term>
<term>Alanine (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (genetics)</term>
<term>Betacoronavirus (pathogenicity)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Drug Repositioning</term>
<term>HIV Infections (drug therapy)</term>
<term>Hepatitis B (drug therapy)</term>
<term>Hepatitis C (drug therapy)</term>
<term>Humans</term>
<term>Influenza, Human (drug therapy)</term>
<term>Interferon-alpha (pharmacology)</term>
<term>Interferon-alpha (therapeutic use)</term>
<term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term>
<term>Middle East Respiratory Syndrome Coronavirus (genetics)</term>
<term>Middle East Respiratory Syndrome Coronavirus (pathogenicity)</term>
<term>Nucleosides (pharmacology)</term>
<term>Nucleosides (therapeutic use)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Polyethylene Glycols (pharmacology)</term>
<term>Polyethylene Glycols (therapeutic use)</term>
<term>Protease Inhibitors (pharmacology)</term>
<term>Protease Inhibitors (therapeutic use)</term>
<term>Recombinant Proteins (pharmacology)</term>
<term>Recombinant Proteins (therapeutic use)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (genetics)</term>
<term>SARS Virus (pathogenicity)</term>
<term>Spike Glycoprotein, Coronavirus (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>AMP (analogues et dérivés)</term>
<term>AMP (usage thérapeutique)</term>
<term>Alanine (analogues et dérivés)</term>
<term>Alanine (usage thérapeutique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (génétique)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (pathogénicité)</term>
<term>Glycoprotéine de spicule des coronavirus ()</term>
<term>Grippe humaine (traitement médicamenteux)</term>
<term>Humains</term>
<term>Hépatite B (traitement médicamenteux)</term>
<term>Hépatite C (traitement médicamenteux)</term>
<term>Infections à VIH (traitement médicamenteux)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Inhibiteurs de protéases (pharmacologie)</term>
<term>Inhibiteurs de protéases (usage thérapeutique)</term>
<term>Interféron alpha (pharmacologie)</term>
<term>Interféron alpha (usage thérapeutique)</term>
<term>Nucléosides (pharmacologie)</term>
<term>Nucléosides (usage thérapeutique)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Polyéthylène glycols (pharmacologie)</term>
<term>Polyéthylène glycols (usage thérapeutique)</term>
<term>Protéines recombinantes (pharmacologie)</term>
<term>Protéines recombinantes (usage thérapeutique)</term>
<term>Repositionnement des médicaments</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (génétique)</term>
<term>Virus du SRAS (pathogénicité)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Interferon-alpha</term>
<term>Nucleosides</term>
<term>Polyethylene Glycols</term>
<term>Protease Inhibitors</term>
<term>Recombinant Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
<term>Antiviral Agents</term>
<term>Interferon-alpha</term>
<term>Nucleosides</term>
<term>Polyethylene Glycols</term>
<term>Protease Inhibitors</term>
<term>Recombinant Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>HIV Infections</term>
<term>Hepatitis B</term>
<term>Hepatitis C</term>
<term>Influenza, Human</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Betacoronavirus</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Inhibiteurs de protéases</term>
<term>Interféron alpha</term>
<term>Nucléosides</term>
<term>Polyéthylène glycols</term>
<term>Protéines recombinantes</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term>
<term>Hépatite B</term>
<term>Hépatite C</term>
<term>Infections à VIH</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
<term>Antiviraux</term>
<term>Inhibiteurs de protéases</term>
<term>Interféron alpha</term>
<term>Nucléosides</term>
<term>Polyéthylène glycols</term>
<term>Protéines recombinantes</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Repositioning</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Humains</term>
<term>Repositionnement des médicaments</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32127666</PMID>
<DateCompleted><Year>2020</Year>
<Month>03</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-1784</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>19</Volume>
<Issue>3</Issue>
<PubDate><Year>2020</Year>
<Month>03</Month>
</PubDate>
</JournalIssue>
<Title>Nature reviews. Drug discovery</Title>
<ISOAbbreviation>Nat Rev Drug Discov</ISOAbbreviation>
</Journal>
<ArticleTitle>Therapeutic options for the 2019 novel coronavirus (2019-nCoV).</ArticleTitle>
<Pagination><MedlinePgn>149-150</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/d41573-020-00016-0</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Guangdi</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>De Clercq</LastName>
<ForeName>Erik</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016433">News</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Nat Rev Drug Discov</MedlineTA>
<NlmUniqueID>101124171</NlmUniqueID>
<ISSNLinking>1474-1776</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009705">Nucleosides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber>
<NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3WJQ0SDW1A</RegistryNumber>
<NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>415SHH325A</RegistryNumber>
<NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber>
<NameOfSubstance UI="D000409">Alanine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>Q46947FE7K</RegistryNumber>
<NameOfSubstance UI="C100416">peginterferon alfa-2a</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009705" MajorTopicYN="Y">Nucleosides</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011480" MajorTopicYN="Y">Protease Inhibitors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>3</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>3</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>3</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32127666</ArticleId>
<ArticleId IdType="doi">10.1038/d41573-020-00016-0</ArticleId>
<ArticleId IdType="pii">10.1038/d41573-020-00016-0</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list></list>
<tree><noCountry><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
<name sortKey="Li, Guangdi" sort="Li, Guangdi" uniqKey="Li G" first="Guangdi" last="Li">Guangdi Li</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000210 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000210 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= CovidV2 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:32127666 |texte= Therapeutic options for the 2019 novel coronavirus (2019-nCoV). }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:32127666" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a CovidV2
This area was generated with Dilib version V0.6.33. |